Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization study of treatment of advanced pulmonary large cell neuroendocrine carcinoma
ChiCTR-INR-16009422Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Oct 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in large cell neuroendocrine carcinoma (LCNEC) comparing Etoposide + Carboplatin with Paclitaxel + Carboplatin (2 arms). Primary endpoint: progression-free survival. Planned start Oct 2016; status: not yet recruiting.
02
Drugs
etoposidecarboplatinpaclitaxel
03
Conditions
large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on ChiCTR-INR-16009422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-INR-16009422.